ADVANCED MAGNETICS COMPLETES ENROLLMENT IN IRON-REPLACEMENT TRIAL

Advanced Magnetics announced it has completed enrollment in a clinical study of ferumoxytol in 230 dialysis-dependent chronic kidney disease (CKD) patients. The trial is the fourth and final planned multicenter study in the company's Phase III development program for ferumoxytol, an intravenous iron-replacement therapeutic for the treatment of anemia in CKD patients.

In this study, patients were randomized to receive either two 510-mg doses of ferumoxytol within one week or 200 mg of oral iron daily for three weeks. The primary endpoint is the mean change in hemoglobin from baseline in the ferumoxytol group compared with that in the oral iron treatment group.

With completion of enrollment in the CKD trial, the company remains on schedule to file a new drug application for ferumoxytol in the fourth quarter of 2007. The company plans to submit data from more than 1,600 CKD patients studied in the overall Phase III program to demonstrate ferumoxytol's safety and clinical benefit.

Results from the three completed Phase III ferumoxytol trials will be presented next month at the National Kidney Foundation 2007 Spring Clinical Meetings.